(2021), Lancet 397(10286), PubMed 33894838 Statistics from preclinical literature Cagrilintide (development code AM833 ), a long-acting amylin analogue , 32 amino acids, molecular weight 3.795 kDa Developed at Novo Nordisk (Denmark) as part of the CagriSema combination program (cagrilintide + semaglutide) Target: amylin receptors (AMY1, AMY2, AMY3) + secondarily the calcitonin receptor , extended half-life via a C16 fatty acid linker Standard dose in clinical trials: 0.164.5 mg/week subcutaneously (Phase 1b/2) Phase 2 (Enebo 2021, n=96): 17.1 % reduction in body weight with CagriSema 2.4 mg + 2.4 mg over 20 weeks vs 9.8 % with semaglutide alone REDEFINE 1 Phase 3 (2024, preliminary data): 22.7 % weight reduction with CagriSema 2.4 mg/2.4 mg over 68 weeks Status: Phase 3 completed 20242025 , FDA filing expected 20252026 Approximately 25+ peer-reviewed publications in PubMed (20182024) Reference sources (PubMed) Enebo LB
Average weight loss was 25 pounds
[DOI] [PMC free article] [PubMed] [Google Scholar] 79.Lee D.-H., Park K.S., Ahn S., Ku E.J., Jung K.Y., Kim Y.J., Kim K.M., Moon J.H., Choi S.H., Park K.S., et al
Exerc 2010;42:180918 Fallah F, Mahdavi R (2023) Ameliorating effects of L-carnitine and synbiotic co- supplementation on anthropometric measures and cardiometabolic traits in women with obesity: a randomized controlled clinical trial
Resources Active Peptide Company
After the initial stages of wound healing are activated, such as blood coagulation and neutrophil invasion, a second stage of wound healing begins, which includes the population of GHK at the wound, which has a high affinity to Cu 2+
